Ann E. Walts

Cedars-Sinai Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Alberto M. Marchevsky

Cedars-Sinai Medical Center

Beth Y. Karlan

University of California, Los Angeles

Sandra Oršulić

VA Greater Los Angeles Healthcare System

Shikha Bose

Cedars-Sinai Medical Center

Arkadiusz Gertych

Cedars-Sinai Medical Center

Dong‐Joo Cheon

Albany Medical Center Hospital

Jessica A. Beach

Peter MacCallum Cancer Centre

Dror Berel

Cedars-Sinai Medical Center

Kenzo Hiroshima

Tokyo Women's Medical University Yachiyo Medical Center

Jenny Lester

University of California, Los Angeles

Cooperative Institutions

Cedars-Sinai Medical Center

184

Rush University Medical Center

131

Columbia College - Missouri

123

University of California, Los Angeles

Massachusetts General Hospital

The University of Texas MD Anderson Cancer Center

John Wiley & Sons (United States)

Università Cattolica del Sacro Cuore

Hudson Institute

Beth Israel Deaconess Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Cancer Letters (2016)

Dongyu Jia Zhenqiu Liu Nan Deng Tuan Zea Tan Ruby Yun‐Ju Huang

Although cancer-associated fibroblasts (CAFs) are viewed as a promising therapeutic target, the design of rational therapy has been hampered by two key obstacles. First, attempts to ablate CAFs have resulted in significant toxicity because currently used biomarkers cannot effectively distinguish activated CAFs from non-cancer associated fibroblasts and mesenchymal progenitor cells. Second, it is unclear whether CAFs in different organs have different molecular and functional properties that necessitate organ-specific therapeutic designs. Our analyses uncovered COL11A1 as a highly specific biomarker of activated CAFs. Using COL11A1 as a 'seed', we identified co-expressed genes in 13 types of primary carcinoma in The Cancer Genome Atlas. We demonstrated that a molecular signature of activated CAFs is conserved in epithelial cancers regardless of organ site and transforming events within cancer cells, suggesting that targeting fibroblast activation should be effective in multiple cancers. We prioritized several potential pan-cancer therapeutic targets that are likely to have high specificity for activated CAFs and minimal toxicity in normal tissues.

Cancer-Associated Fibroblasts

Gene signature

10.1016/j.canlet.2016.09.001

Cite

Citations (108)

Multiplatform Molecular Test Performance in Indeterminate Thyroid Nodules

Journal of the American Society of Cytopathology (2020)

Mark A. Lupo Shikha Bose Ann E. Walts J. Woody Sistrunk Thomas J. Giordano

Immunofluorescence

10.1016/j.jasc.2020.07.127

Cite

Citations (3)

Supplementary Tables from A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer

Dong‐Joo Cheon Yunguang Tong Myung‐Shin Sim Judy Dering Dror Berel

<p>XLS file 139K, Supplementary Tables. Supplementary Table 1A-C. Poor prognosis genes identified from 3 different datasets (A) TCGA, (B) GSE26712, (C) Karlan. Supplementary Table 2. Functional annotation of poor prognosis genes in three datasets. Supplementary Table 3. PCR primer sequences. Supplementary Table 4. Genes and corresponding probes used for Oncomine analysis of expression in primary tumors and metastases. Supplementary Table 5.Matched primary, metastatic and recurrent tumor samples -</p>

Table (database)

Serous ovarian cancer

10.1158/1078-0432.22448159

Cite

Citations (0)

Lymphoid-rich Effusions:Diagnosis by Morphometry Using the CAS 200 System^™

American Journal of Clinical Pathology (1994)

Ann E. Walts Romina Svidler Tanya Tolmachoff Alberto M. Marchevsky

Lymphoid-rich effusions frequently present diagnostic problems in clinical cytology. In the authors' previous studies, most lymphoid-rich effusions had been correctly classified as benign lymphocytosis or malignant lymphoma by an experimental computerized interactive morphometry system, in which randomly selected lymphoid nuclear profile images were measured in Papanicolaou fixed and stained cytospin smears. The present study used the CAS 200 System and criteria from the previously described rule-based expert system to classify similar preparations of 134 lymphoid rich pleural, peritoneal, and pericardial effusions (90 benign lymphocytoses, 36 malignant lymphomas, and 8 chronic lymphocytic leukemias). A total of 98.9% of the benign lymphocytoses and 88.9% of the malignant lymphomas were correctly classified (predictive values of correct diagnoses 95.7% and 97.3%, respectively). Chronic lymphocytic leukemias could not be distinguished from benign lymphocytoses by nuclear profile areas. Optical density histograms of benign, lymphomatous, and chronic lymphocytic leukemias effusions are described. Advantages and limitations of image analysis and immunocytochemistry are discussed.

Lymphocytosis

Pseudolymphoma

10.1093/ajcp/101.4.526

Cite

Citations (12)

Next-Generation Sequencing

Journal of Molecular Diagnostics (2017)

Snehal Patel Wendy Kadi Ann E. Walts Alberto M. Marchevsky Andy Pao

10.1016/j.jmoldx.2017.07.006

Cite

Citations (55)

Fine needle aspiration of the thyroid-review of a valuable diagnostic technique

Clinical Otolaryngology (1982)

Ann E. Walts

Cytopathology

Section (typography)

Medical library

Center (category theory)

Hematopathology

10.1111/j.1365-2273.1982.tb01584.x

Cite

Citations (3)

Multiplatform molecular test performance in indeterminate thyroid nodules

Diagnostic Cytopathology (2020)

Mark A. Lupo Ann E. Walts J. Woody Sistrunk Thomas J. Giordano Peter M. Sadow

Approximately 25% of thyroid nodule fine-needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Accurate risk stratification of these FNAs with ancillary testing would reduce unnecessary thyroid surgery.We evaluated the performance of an ancillary multiplatform test (MPTX) that has three diagnostic categories (negative, moderate, and positive). MPTX includes the combination of a mutation panel (ThyGeNEXT®) and a microRNA risk classifier (ThyraMIR®). A blinded, multicenter study was performed using consensus histopathology diagnosis among three pathologists to validate test performance.Unanimous consensus diagnosis was reached in 197 subjects with indeterminate thyroid nodules; 36% had disease. MPTX had 95% sensitivity (95% CI,86%-99%) and 90% specificity (95% CI,84%-95%) for disease in prevalence adjusted nodules with Bethesda III and IV cytology. Negative MPTX results ruledout disease with 97% negative predictive value (NPV; 95% CI,91%-99%) at a 30% disease prevalence, while positive MPTX results ruledin high risk disease with 75% positive predictive value (PPV; 95% CI,60%-86%). Such results are expected in four out of five Bethesda III and IV nodules tested, including RAS positive nodules in which the microRNA classifier was useful in rulingin disease. 90% of mutation panel false positives were due to analytically verified RAS mutations detected in benign adenomas. Moderate MPTX results had a moderate rate of disease (39%, 95% CI,23%-54%), primarily due to RAS mutations, wherein the possibility of disease could not be excluded.Our results emphasize that decisions for surgery should not solely be based on RAS or RAS-like mutations. MPTX informs management decisions while accounting for these challenges.

Indeterminate

Thyroid Nodules

10.1002/dc.24564

Cite

Citations (88)

Lung transplantation: the pathologic diagnosis of pulmonary complications.

PubMed (1991)

Alberto M. Marchevsky Gary E. Hartman Ann E. Walts David J. Ross Spencer K. Koerner

Diffuse alveolar damage

Pulmonary Infarction

Pneumonitis

Source

Cite

Citations (13)

PI3K pathway activation and thromboembolism in ovarian clear cell carcinomas

Gynecologic Oncology (2012)

E. Diaz Nicole D. Fleming Hoorig Nassanian Ann E. Walts Deborah A. Zajchowski

Clear cell carcinoma

Phosphoinositide 3-kinase

Ovarian carcinomas

10.1016/j.ygyno.2012.07.005

Cite

Citations (0)

Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas

Pathology International (2021)

Kenzo Hiroshima Di Wu Eitetsu Koh Yasuo Sekine Daisuke Ozaki

Sialylated HEG1 has been reported as a highly specific and sensitive mesothelioma marker but a comprehensive evaluation of its expression in carcinomas in different organs, various sarcomas and reactive mesothelial proliferations has not been reported. The aim of this study was to evaluate the clinical applicability of HEG1 as a marker in the diagnosis of mesothelioma. HEG1 immunoreactivity was evaluated in whole sections of 122 mesotheliomas, 75 pulmonary carcinomas, 55 other carcinomas, 16 mesenchymal tumors, and 24 reactive mesothelial proliferations and in tissue microarrays containing 70 epithelioid (EM), 36 biphasic (BM), and 2 sarcomatoid mesotheliomas (SM). In whole sections and tissue microarrays, respectively, membranous HEG1 was expressed in 93.0% and 85.5% of EM, 81.3% and 69.4% of BM, 0% and 0% of SM. HEG1 was not expressed in pulmonary adenocarcinomas. HEG1 was expressed as cytoplasmic immunoreactivity in pulmonary squamous cell carcinomas (21.7%). Membranous HEG1 staining was seen in ovarian carcinomas (66.7%), thyroid carcinomas (100%), reactive conditions (16.7%), and mesenchymal tumors (18.8%). The sensitivity of membranous HEG1 expression to distinguish EM/BM from all carcinomas was 88.8%. The specificity for the differential diagnosis between EM/BM and all carcinomas and pulmonary carcinomas was 92.3% and 98.7%, respectively.

Tissue microarray

10.1111/pin.13140

Cite

Citations (13)